Soblidotin

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameSoblidotin
Drug Alias Namesoblidotinum索利多丁soblidotinasoblidotineAuristatin PE +[8
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursLung NeoplasmsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAska Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsSolid tumoursLung NeoplasmsSarcoma

Other Information

ATC CodeN/A
Related LinksKEGG